Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?

Key Takeaways DHR is set to report Q3 2025 results on Oct. 21, with revenues estimated at $6.00 billion.Life Sciences may face softness, while Biotechnology gains from strong bioprocessing demand.Diagnostics likely grew modestly, aided by the Beckman Coulter unit and steady clinical demand.Danaher Corporation (DHR) is scheduled to release third-quarter 2025 results on Oct. 21, before market open.The Zacks Consensus Estimate for revenues is pegged at $6.00 billion, which indicates an increase of 3.4% from th ...